In the rapidly evolving landscape of healthcare, genetic testing is emerging as a pivotal force, promising to transform patient care through precision medicine. The insights derived from our genetic codes hold the potential to not only prevent diseases but also optimize treatments and promote healthier living. Yet, as highlighted in a recent MedCity News article, the journey towards realizing this potential is fraught with challenges, particularly around patient privacy and data sharing.
The Role of Information Technology
A critical component in addressing these challenges is information technology security. Organizations are turning to certifications like HITRUST to establish standards for safeguarding sensitive information. By aligning with these standards, they can protect data while facilitating the sharing necessary to enhance medical knowledge and patient care.
Collaborative Efforts and Data Sharing
Collaboration is at the heart of advancing genetic testing. Companies are contributing de-identified variant data to public health databases such as ClinVAR and the SEER Cancer Registries. These efforts, supported by cancer research registries, deepen insights and expedite advancements in patient care.
The analysis of expansive data sets is crucial for understanding diseases, allowing researchers to access, assess, and test hypotheses. This collaborative approach is paving the way for tailored treatment plans and new biological discoveries, enhancing early disease detection and intervention.
Integration with Electronic Health Records
Integrating genetic testing with Electronic Health Records (EHR) is another key strategy for improving patient outcomes. Collaborations with EHR vendors like Epic, Flatiron, and Athena streamline processes, making it easier for providers to order genetic products, optimize screening protocols, and identify potential pharmacogenetic interactions. Such collaborations break down silos, enhancing data exchange for more effective research and patient care.
Challenges and Future Trends
Despite the promising progress, the integration of genetic testing into mainstream medicine presents challenges, including managing the vast volume of genomic data. Companies are focusing on presenting complex clinical interpretations, integrating common data ontologies, overcoming data fragmentation, and ensuring data privacy to address these hurdles.
Looking ahead, the industry anticipates significant advancements, with trends like developing tests for early cancer recurrence detection and embracing a multi-omics approach that integrates RNA, proteins, and AI insights. The integration of generative AI for documentation and genetic counseling is another notable development on the horizon.
A New Era in Healthcare
Genetic testing represents more than just a scientific advancement; it signifies a fundamental shift in how we approach health and wellness. As public understanding grows and technology advances, we find ourselves at the dawn of a new era in healthcare, where our genetic code becomes a roadmap to better health and longevity.
About the Author
Kevin Haas, Ph.D., serves as the Chief Technology Officer at Myriad Genetics, where he leads the development of the precision medicine platform. With expertise in molecular simulation and machine learning, Haas is advancing genomics and digital patient/provider experiences. He has co-authored 16 peer-reviewed publications and nine patent applications, bringing a wealth of experience to his role.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Bluerate.ai—formerly MyMortgageRates—is stepping into 2025 with a mission to modernize a mortgage process that has barely changed in decades. Built by Zeitro, the platform equips both borrowers and loan officers with powerful AI tools, from online pre‑qualification and automated financial data extraction to instant guideline answers and scenario analysis. With more than 3,000 verified NMLS‑licensed loan officers and real‑time rate comparisons from major lenders, Bluerate.ai is quickly becoming a must‑know platform for mortgage and real estate professionals seeking speed, clarity, and a fully digital lending experience.
After the longest government shutdown in U.S. history, key federal housing programs such as FHA, VA, USDA, and NFIP are officially back in operation—offering long‑awaited relief to agents, lenders, and insurance professionals. But with a six‑week backlog slowing everything from loan guarantees to flood-insurance renewals, real estate pros should brace for delays and focus on resetting client expectations. A new federal spending deal restores funding through early 2026 and gives the market room to breathe, while NAR’s aggressive advocacy helped push the government toward reopening. Now, professionals who communicate clearly and stay on top of regulatory updates will be best positioned to guide clients through the temporary turbulence.
Commercial real estate is rapidly shifting toward a digital-first model, with platforms like Crexi leading the charge. By unifying property data, AI-driven insights, transparent bidding, and streamlined transaction tools, digital marketplaces are becoming essential to how modern CRE deals are sourced, analyzed, and closed. With more than 2 million monthly users and over $1 trillion in facilitated transactions, Crexi showcases how technology is reshaping the industry and giving real estate professionals a powerful competitive edge.
Europe’s biggest landlords—including Aroundtown, Vonovia, and top global investors—have teamed up to launch ATechX, a powerful new accelerator giving proptech startups something they rarely get: access to real buildings, real customers, and a clear path to scale across multiple countries. Designed to move founders beyond “pilot purgatory,” ATechX offers a true sandbox for innovation in Europe’s aging, regulation‑heavy property market, helping promising technology reach commercial traction faster than ever.
Mortgage rates are finally easing, inventory is climbing, and buyers are gaining leverage for the first time in years — yet sky‑high prices and economic jitters are keeping many on pause. With economists warning that inflation could push rates higher again, this fall may offer a rare window for well‑prepared buyers. Here’s what’s driving the shift, where opportunities are emerging, and how real estate professionals can stay ahead.
Griffin Funding has appointed John Jones as Senior Vice President of Growth and EOS Integrator, aiming to scale the company toward a $3 billion annual non-QM volume goal by 2030. After serving in fractional leadership roles since April 2025, Jones now steps in full‑time to lead organizational structure, efficiency, market expansion, and cross‑department alignment. Backed by strong liquidity and rising deal volume, Griffin Funding appears positioned for major industry impact in the years ahead.
